Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Adma Biologics (ADMA) over the last 6 years, with Q3 2025 value amounting to $245.5 million.

  • Adma Biologics' Shares Outstanding (Diluted Average) rose 28.07% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 28.07%. This contributed to the annual value of $243.3 million for FY2024, which is 864.6% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Shares Outstanding (Diluted Average) is $245.5 million, which was up 28.07% from $248.6 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Shares Outstanding (Diluted Average) registered a high of $248.6 million during Q2 2025, and its lowest value of $115.7 million during Q1 2021.
  • For the 5-year period, Adma Biologics' Shares Outstanding (Diluted Average) averaged around $205.8 million, with its median value being $222.7 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 6934.87% in 2022, then rose by 28.07% in 2025.
  • Over the past 5 years, Adma Biologics' Shares Outstanding (Diluted Average) (Quarter) stood at $139.6 million in 2021, then surged by 41.77% to $197.9 million in 2022, then rose by 13.19% to $224.0 million in 2023, then increased by 8.65% to $243.3 million in 2024, then rose by 0.88% to $245.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $245.5 million in Q3 2025, compared to $248.6 million in Q2 2025 and $244.7 million in Q1 2025.